Overview

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of treatment with 24 weeks nitazoxanide monotherapy on end of treatment virologic response, sustained virologic response, reduction of quantitative serum HCV RNA, changes in ALT and safety parameters.
Phase:
Phase 2
Details
Lead Sponsor:
Romark Laboratories L.C.
Treatments:
Nitazoxanide